newsfilter
← Latest News
GlobeNewswire·

Codexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing Capabilities

  • Codexis presented new ECO Synthesis® platform data at TIDES Europe 2026 demonstrating quality, stereo-control, & manufacturing performance for siRNA therapeutics.
  • The platform achieved over 90% product quality at the 100-gram scale while nearly halving cycle time.
  • Manufacturing performance remained consistent across three orders of magnitude in scale.
  • The company demonstrated efficient incorporation of tissue-targeting moieties for optimized siRNA design.
  • Biological data showed siRNA with defined phosphorothioate stereochemistry had a 3- to 4-fold increase in potency compared to chemically synthesized versions in human hepatocyte models.
  • Stefan Lutz, Chief Scientific Officer, stated that molecular precision enables additional tools for next-generation RNA therapeutic design.
  • Codexis continues to advance its proprietary ECO Synthesis platform toward industrialization & adoption readiness for scalable RNA manufacturing.
Company
Codexis, Inc.
Keywords
Nasdaq:CDXS, Codexis, Inc.